These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 1979818

  • 21. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [Abstract] [Full Text] [Related]

  • 22. Alpha-blockade for hypertension: indifferent past, uncertain future.
    Lancet; 1989 May 13; 1(8646):1055-6. PubMed ID: 2566006
    [No Abstract] [Full Text] [Related]

  • 23. [Effects of terazocin on hypertensive patients].
    Liu G.
    Zhonghua Xin Xue Guan Bing Za Zhi; 1990 Oct 13; 18(5):271-2. PubMed ID: 1982259
    [No Abstract] [Full Text] [Related]

  • 24. Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
    Rosenthal J, Kyncl JJ.
    J Clin Pharmacol; 1993 Sep 13; 33(9):866-7. PubMed ID: 7901240
    [No Abstract] [Full Text] [Related]

  • 25. Terazosin for BPH.
    Jerant AF.
    J Fam Pract; 1995 Mar 13; 40(3):222-3. PubMed ID: 7533204
    [No Abstract] [Full Text] [Related]

  • 26. Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension.
    Pool JL, Nelson EB, Taylor AA, Mitchell JR.
    Br J Clin Pract Suppl; 1987 Dec 13; 54():9-14. PubMed ID: 2905162
    [No Abstract] [Full Text] [Related]

  • 27. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N.
    J Urol; 2003 Apr 13; 169(4):1520-5. PubMed ID: 12629407
    [Abstract] [Full Text] [Related]

  • 28. [ALLHAT Study: doxazosin arm is discontinued. Alpha blocker is less effective than a diuretic].
    Einecke D.
    MMW Fortschr Med; 2000 Mar 30; 142(13):4-5. PubMed ID: 10783613
    [No Abstract] [Full Text] [Related]

  • 29. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P.
    J Hypertens Suppl; 1992 Jun 30; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [Abstract] [Full Text] [Related]

  • 30. Frontiers in cardiology: Alpha blockade and coronary heart disease risk reduction. Symposium, Washington, D.C., September 16, 1986.
    Am J Med; 1987 Jan 05; 82(1A):1-63. PubMed ID: 2879459
    [No Abstract] [Full Text] [Related]

  • 31. Alpha blockade in preoperative preparation of patients with pheochromocytomas.
    Kocak S, Aydintug S, Canakci N.
    Int Surg; 2002 Jan 05; 87(3):191-4. PubMed ID: 12403097
    [Abstract] [Full Text] [Related]

  • 32. Clinical model for antihypertensive therapy in the 1990s: the role of alpha1 blockade. Proceedings of a symposium. Irving, Texas, November 8-10, 1990.
    Am Heart J; 1991 Sep 05; 122(3 Pt 2):885-942. PubMed ID: 1678917
    [No Abstract] [Full Text] [Related]

  • 33. Acute effects of doxazosin and atenolol on smoking-induced peripheral vasoconstriction in hypertensive habitual smokers.
    Lecerof H, Bornmyr S, Lilja B, De Pedis G, Hulthén UL.
    J Hypertens Suppl; 1990 Sep 05; 8(5):S29-33. PubMed ID: 1981074
    [Abstract] [Full Text] [Related]

  • 34. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C, Ferrier C, Weidmann P.
    J Hypertens Suppl; 1985 Dec 05; 3(3):S231-4. PubMed ID: 2908818
    [Abstract] [Full Text] [Related]

  • 35. Advances in the management of hypertension: focus on terazosin, a new alpha1-adrenergic antagonist. May 3-5, 1985, Boca Raton, Florida.
    Am J Med; 1986 May 23; 80(5B):1-105. PubMed ID: 2872798
    [No Abstract] [Full Text] [Related]

  • 36. Doxazosin: A distinctive approach to risk reduction of coronary heart disease in hypertensive patients. Proceedings of a symposium. Hamburg, West Germany, January 30, 1988.
    Am Heart J; 1988 Dec 23; 116(6 Pt 2):1707-840. PubMed ID: 2974237
    [No Abstract] [Full Text] [Related]

  • 37. [Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension].
    Yang MG, Zhao XK.
    Zhonghua Nan Ke Xue; 2007 Sep 23; 13(9):830-4. PubMed ID: 17929564
    [Abstract] [Full Text] [Related]

  • 38. Doxazosin in 'resistant' hypertension.
    Maclean D, McDevitt DG.
    J Hum Hypertens; 1990 Oct 23; 4 Suppl 3():50-1. PubMed ID: 1979820
    [Abstract] [Full Text] [Related]

  • 39. Hypertension and alpha-adrenergic blockers: preliminary ALLHAT results.
    Chen BH.
    CMAJ; 2000 Aug 22; 163(4):437. PubMed ID: 10976266
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.